Company intelligence / Profile preview

BJ Bioscience Inc.

Ownership: Private
Employees: ~20
Development stage: Phase 1

Overview

BJ-001, the company's lead asset, has demonstrated tolerable safety profiles, favorable PK/PD profiles, and encouraging preliminary efficacy results in monotherapy dose escalation cohorts. The company is currently evaluating BJ-001 in combination with MSD's KEYTRUDA in patients with locally advanced/metastatic solid tumors[4][6].

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Bispecific antibodiesMonoclonal antibodiesFusion proteins
Industry: Biotech

Drug pipeline

3 assets

BJ-005

2 more assets in the full pipeline.

Request access →

Partnerships

MSD (Merck & Co., Inc.) for clinical trial collaboration to evaluate BJ-001 in combination with KEYTRUDA (pembrolizumab)[4]

Beyond the preview

Go deeper on BJ Bioscience Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BJ Bioscience Inc..

Explore the full profile